Population Attributable Fractions for Late Postnatal Mother-to-Child Transmission of HIV-1 in Sub-Saharan Africa by Chen, Ying Q et al.
Population Attributable Fractions for Late Postnatal Mother-to-
Child Transmission of HIV-1 in Sub-Saharan Africa
Ying Q. Chen, PhD*, Alicia Young, MS*, Elizabeth R. Brown, ScD†,*, Charles S. Chasela,
MSc‡, Susan A. Fiscus, PhD§, Irving F. Hoffman, MPH§, Megan Valentine, MS∥, Lynda Emel,
PhD*, Taha E. Taha, MD, PhD¶, Robert L. Goldenberg, MD#, and Jennifer S. Read, MD**
* Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research
Center, Seattle, WA
†Department of Biostatistics, University of Washington, Seattle, WA
‡University of North Carolina Project, Kamuzu Central Hospital, Lilongwe, Malawi
§University of North Carolina, Chapel Hill, NC
∥Science Facilitation Department, the Family Health International, Durham, NC
¶Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
#Department of Obsterics and Gynecology, Drexel College of Medicine, Philadelphia, PA
**Pediatric, Adolescent, and Maternal AIDS Branch, CRMC, NICHD, NIH, DHHS, Bethesda, MD.
Abstract
Objectives—Assess population attributable fractions (PAFs) for late postnatal transmission
(LPT) of human immunodeficiency virus-1 (HIV-1) in a cohort of HIV-1-exposed infants.
Methods—We used data established from a risk factor analysis of LPT (negative HIV-1 results
through the 4-6 week visit, but positive assays thereafter through the 12-month visit) from a
perinatal clinical trial conducted in three sub-Saharan countries. PAFs were calculated as the
proportions of excess LPTs attributed to identified risk factors.
Results—For the cohort of 1317 infants, 206 (15.6%) had only low maternal CD4+ counts (<
200 cells/mm3), 332 (25.2%) had only high maternal plasma viral loads (VLs) (> 50 000 copies/
mL), and 81 (6.2%) had both low CD4+ counts and high VLs. Their PAFs were 26.0% [95%
confidence interval (CI), 12.0%-36.0%], 37.0% (95% CI, 22.0%-51.0%) and 16.0% (95% CI,
6.0%-25.0%), respectively.
Conclusions—Our PAF analysis illustrates the public health impact of the substantial
proportion of LPTs accounted for by high-risk women with both low CD4+ counts and high VLs.
In light of these results, access to and use of antiretroviral therapy (ART) by high-risk HIV-1-
infected pregnant women is essential. Additional strategies to reduce LPT for those not meeting
criteria for ART should be implemented.
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In resource-limited areas where efficacious interventions to prevent mother-to-child
transmission (MTCT) of human immunodeficiency virus type-1 (HIV-1) such as
antiretroviral prophylaxis, cesarean section before labor and ruptured membranes, and
complete avoidance of breastfeeding are not universally available or feasible, the risk of
MTCT of HIV-1 remains high. It is estimated that the rate of MTCT of HIV-1 could be as
high as 42.0% in the absence of any intervention to prevent transmission 1 In 2007, an
estimated 270,000 children younger than 15 years died of AIDS, and, of those, more than
90.0% were from sub-Saharan Africa 2-3. In those most heavily-affected countries, HIV-1 is
the underlying reason for one-third of the deaths among children aged five years or
younger 4. Without antiretroviral therapy (ART), HIV disease progression in children is
particularly aggressive, with many children dying at a very young age 4-7.
In sub-Saharan Africa, prolonged breastfeeding is customary. Breast milk transmission is
one of the most important mechanisms through which MTCT of HIV-1 occurs. In an
individual patient data meta-analysis including data from more than 3,000 breastfeeding
infants of HIV-1-infected women from sub-Saharan Africa, the cumulative probability of
late postnatal transmission (LPT) at 18 months was estimated to be 9.3%, and the overall
LPT incidence rate was estimated to be 8.9 per 100 child-years of breastfeeding 1,7.
The HIV Network for Prevention Trials (HIVNET) 024 trial was a randomized clinical trial
to assess the efficacy of antibiotics to prevent chorioamnionitis-associated MTCT of HIV-1
and preterm birth in sub-Saharan Africa 8-9. A secondary analysis of risk factors for LPT
identified that lower maternal CD4+ counts and higher plasma viral loads at enrollment were
significantly associated with higher risk of LPT of HIV-110.
Although lower maternal CD4+ counts and higher maternal plasma viral loads are
significant risk factors for LPT, the public health impact of these risk factors by their
amelioration (e.g., through effective ART) has rarely been investigated. Toward this end,
this analysis aims to evaluate the public health impact, by studying the population
attributable fractions (PAFs) of LPTs (breastfeeding transmissions) attributed to low
maternal CD4+ counts and/or high maternal plasma viral loads.
Generally speaking, the PAF has been extensively used as an epidemiological parameter to
measure the public health impact attributed to being exposed to a risk factor 11-13, although
it should be cautiously interpreted in practice 14. For example, a PAF of 15% means that the
risk factor would account for 15% of the population disease incidence, and it implies that the
population disease incidence would potentially be reduced by 15% if the risk factor were
removed from the population. In this analysis, we calculated the PAFs for the identified risk
factors of LPTs, to investigate the potential public health implication of amelioration of
these risk factors in the HIVNET 024 population. These PAFs, as calculated, are directly
related to the sub-Saharan Africa population where the HIVNET 024 study was conducted.
Hence, they can be used to assess the impact of low maternal CD4+ counts and high viral
loads on breastfeeding transmission (and the potential effect of identifying and treating the
high risk group of women with low CD4+ counts and high viral loads).
METHODS
The HIVNET 024 Trial
The HIVNET 024 trial was conducted at four sites in three sub-Saharan African countries:
Blantyre and Lilongwe, Malawi; Dar es Salaam, Tanzania; and Lusaka, Zambia. Details
regarding the methods and results of this randomized trial have been published 8-9. The
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protocol, outcome measures and interview details are available at:
http://www.hptn.org/research_studies/hivnet024.asp. The study was approved by the
institutional review boards at each participating institution, and participants provided written
informed consent. All enrolled HIV-1-infected women and their infants were given
nevirapine (NVP) according to the HIVNET 012 regimen for prevention of MTCT of
HIV-1 16. Infant study visits were conducted at birth (within the first 48 hours), at four to six
weeks, and at three, six, nine, and 12 months. Information about breastfeeding and maternal
health also was collected at these visits. Each clinical site provided HIV-1 counseling
regarding the risks and benefits of breast feeding. However, replacement feeding or other
inventions to prevent breastfeeding-related transmission of HIV-1 infection were not
provided as part of the trial. ART for mothers and children was not available at the
participating clinical sites when the trial was conducted. HIV-1 RNA PCR assays and HIV-1
enzyme immunoassays (EIAs) were used to establish the HIV-1 infection status of infants in
the HIVNET 024 study. Laboratory procedures have been described previously 10.
Definitions and Study Population for This Analysis
The study population for this analysis is identical to the one established for the risk factor
analysis of LPT of HIV-1 in the HIVNET 024 population 10. Specifically, the study
population comprised live born, singleton (or first born if a multiple gestation pregnancy)
infants of HIV-1-infected women enrolled in the HIVNET 024 trial, with negative HIV-1
diagnostic assay results at birth and 4-6 weeks of age, who had subsequent HIV-1 diagnostic
testing performed, and who continued to breastfeed after six weeks of age. Infants with
positive HIV-1 RNA assays at birth were considered to have acquired HIV-1 infection in
utero. Those with a first positive assay at the six-week study visits were considered to have
acquired HIV-1 infection through perinatal/early postnatal transmission. Infants with
negative HIV-1 RNA assay results at birth and at 4-6 weeks of age, but who had positive
HIV-1 RNA test results thereafter through the 12-month visit, were considered to have
acquired HIV-1 infection during the late postnatal period (HIV-1 acquired through
breastfeeding, or LPT). HIV-1-uninfected infants were those with negative EIA results at 12
months of age, or with negative HIV-1 RNA assay results throughout follow-up.
Statistical Analysis
The outcomes of LPT of HIV-1 (through 12 months) were assessed in time-to-event
analyses. The event-time of an infected infant was determined by the midpoint between the
last negative and the first positive HIV-1 RNA assay results (subsequent to the 6-week visit
and at or before the 12-month visit) since an HIV RNA negative result at the 6-week visit,
which is the time-zero of this analysis An event-time was considered censored at the date of
the last negative HIV-1 RNA test result if the infant did not test positive at or before the 12-
month visit. Additional censoring was considered if weaning or death occurred. Discrete-
time Cox proportional hazards models 15 stratified by site were used to identify risk factors
associated with LPT of HIV-1.
To calculate PAF for a risk factor, E, the PAF was defined by
, where I was the total LPT incidence of HIV-1 during the postnatal period and I0 was the
expected LPT incidence for the reference group being unexposed to E 11-13. Unless stated
otherwise, PAFs were calculated under the Cox proportional hazards model. Their variances
were calculated by the developed methods 13. All statistical calculations and analyses were
performed using SAS version 9.1.3 on Sun OS 5.9 platform.
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Risk Factors for LPT of HIV-1
Among a total of 2659 women enrolled in the HIVNET 024 trial, 2292 were HIV-1-
infected. Of their infants, 1317 had negative HIV-1 diagnostic assay results at six weeks of
age, continued to breast-feed after six weeks of age, and had subsequent HIV-1 diagnostic
testing performed. For the 1317 infants who were subsequently followed during the late
postnatal period up to one year of age, 84 LPTs were observed after 6 weeks but before 12
months of age 10. Analysis based on Kaplan-Meier curves showed that the LPT rates by 6
months and 12 months were 4.1% [95% confidence interval (CI): 5.2%-5.4%] and 6.9%
(95% CI: 5.6%-8.5%), respectively. More descriptive results, such as prevalences of the risk
factors, can be found in an earlier publication 10.
For multivariate analyses, maternal characteristics at enrollment (age, education, marital
status, home electricity use, home running water use, CD4+ count, plasma viral load,
cervicovaginal fluid viral load), around the time of delivery (receipt of NVP prophylaxis),
and at 4-6 weeks postpartum (mastitis, cracked nipples), and infant characteristics
(gestational age at birth, birth weight, gender, receipt of NVP prophylaxis, oral candidiasis
at 4-6 weeks of age and infant diarrhea at 4-6 weeks of age) were incorporated 10. In the
earlier final multivariate analysis of using a backward stepwise modeling procedure, lower
maternal CD4+ counts and higher maternal plasma viral loads at enrollment were the two
factors found to be significantly associated with LPT 10. Among the infants who were at risk
of LPT in this cohort, 206 (15.6%) had low maternal CD4+ counts (defined as less than 200
cells/mm3 for the current analysis), and 332 (25.2%) had high maternal viral loads (defined
as more than 50 000 copies/mL for the current analysis). Furthermore, 29 (14.1%) LPTs
were observed among the 206 infants with low maternal CD4+ counts, whereas 49 (5.0%)
LPTs were observed among the 975 infants with higher maternal CD4+ counts (defined as
200 cells/mm3 or more for this analysis). Forty-two (12.7%) LPTs were observed among
332 infants with high maternal viral loads, whereas 37 (4.0%) LPTs were observed among
919 infants with lower maternal viral loads (defined as 50 000 copies/mL or less for this
analysis).
Population Attributable Fractions
The PAFs were estimated as 26.0% (95% CI, 11%-36.0%) for low CD4+ counts and 37.0%
(95% CI, 22.0%-51.0%) for high viral loads: 15.6% of the infants with low maternal CD4+
counts accounted for 26.0% of the total LPTs, and 25.2% of the infants with high maternal
viral loads accounted for 37.0% of the total LPTs. From a risk prevention perspective for
this cohort of infants, if the 15.6% of infants whose mothers had low CD4 counts were to
have an increase in their CD4+ counts to 200 cells/mm3 or more, the overall disease burden
of LPTs would be reduced by 26.0%, and if the 25.2% of infants whose mothers had high
viral loads were to have a decrease in their plasma viral loads to 50 000 copies/mL or less,
the overall disease burden would be reduced by 37.0% (Table 1).
PAFs might fluctuate during the late postnatal period. A person-year analysis showed that
point estimates of the LPT incidence rates were likely to be different between the first part
of the late postnatal period (six weeks to six months) and the second part of the late
postnatal period (six months to 12 months), although a larger sample size may be needed to
show whether or not the differences are statistically significant (Table 2). Similarly, the
PAFs of low maternal CD4+ counts were 32.0% and 14.0%, and the PAFs of high maternal
plasma viral loads were 22.0% and 59.0%, for these two parts of the late postnatal period,
respectively (Table 1).
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Maternal CD4+ counts and viral loads were negatively correlated, as shown in their scatter
plot with a lowess curve (bandwidth = 200) (Figure 1). This negative correlation implies that
the maternal CD4+ counts increase as the viral load decreases, and vice versa. A binary
CD4-VL factor of combined maternal CD4+ counts and viral loads was formed. In the
reference group of 1045 infants with higher maternal CD4+ counts or lower maternal viral
loads, 58 (5.5%) LPTs were observed. In the comparison group of 81 infants with low
maternal CD4+ counts and high viral loads, 16 (19.7%) LPTs were observed. Kaplan-Meier
estimates showed that the comparison group had a greater risk of LPT over time (Figure 2).
In a multivariate regression analysis including all the aforementioned candidate variables
and the combined CD4-VL factor, the combined CD4-VL factor became the sole significant
variable in the full multivariate Cox model, with a hazards ratio of 4.50 (P < 0.0001). The
final Cox model with the only CD4-VL factor showed little change in the hazards ratio.
For the CD4-VL factor, the PAF was calculated as 16.0% (95% CI, 6.0%-25.0%). That is,
although only 6.2% of the infants were in the high-risk subgroup, they disproportionally
accounted for 16.0% of the total LPTs. From a risk prevention perspective, in this high-risk
group, if the 6.2% of mothers had either increased their CD4+ counts to 200 cells/mm3 or
more, or decreased their plasma viral loads to 50,000 copies/mL or less, the total LPT
disease burden would be reduced by 16.0%. Such a reduction would be 15.0% for the first
part of the late postnatal period, and 19.0% for the second part of the late postnatal period
(Table 1).
DISCUSSION
In this large cohort of HIV-1-infected women and their infants from three sub-Saharan
African countries, low maternal CD4+ counts and high maternal viral loads were found to be
significantly associated with the LPT of HIV-1 10. The public health impact of reducing
LPTs in sub-Saharan population by effectively ameliorating these risk factors has rarely
been investigated. Our PAF assessment showed that, for the high-risk group of infants born
to HIV-1-infected mothers with low CD4+ counts and high viral loads in HIVNET 024, if
the maternal CD4+ counts increased to 200 cells/mm3 or more, or the viral loads decreased
to 50,000 copies/mL or less, the total LPT of HIV-1 would be reduced by 16.0%, although
this high-risk group only accounted for 6.2% of the study cohort. In fact, our additional
assessment shows similar PAF crude and model-based estimates.
Numerous studies have demonstrated that low maternal CD4+ absolute lymphocyte counts
and high maternal plasma viral loads are significantly associated with breast milk
transmission of HIV-1 17-23. However, what is less well characterized is the potential impact
of these factors on the overall disease burden of LPT (for example, if maternal CD4+ counts
were increased or maternal viral loads were decreased with timely and appropriate use of
effective ART). Our finding of a potential reduction of 16.0% of the overall LPT burden by
increasing maternal CD4+ counts to 200 cells/mm3 or more, or deceasing maternal viral
loads to 50 000 copies/mL or less, is similar to what was reported in a prospective cohort
study conducted in Thailand 24. In that study, with only maternal viral load being
considered, the PAFs were 21.4% for those with maternal viral loads between 31 622 and
100 000 copies/mL, and 16.2% for those with maternal viral loads above 100 000 copies/
mL.
A particular strength of our analysis is that maternal CD4+ counts and maternal viral loads
were considered jointly by the combined CD4-VL variable. This approach has two
advantages. First, even though these two risk factors were both associated with LPT, their
negative correlation would usually not allow for one to change while the other is held
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constant in a particular intervention/prevention strategy. The combined CD4-VL variable
captured the significant associations of both risk factors, with a proportion of treatment
explained (PTE) of 100% 25. Second, a high-risk group was identified to assess its PAF so
that a prevention program might be prioritized to focus on this group. For the HIVNET 024
cohort, for example, PAFs for the combined CD4-VL variable showed that a prevention
strategy could efficiently reduce a substantial proportion of total LPTs by focusing on one or
more high-risk subgroups, when resources are limited.
There are limitations of our analysis. First, the mothers who agreed to participate in
HIVNET 024 might not be representative of the entire population that a potential prevention
program would target, since they had to satisfy certain inclusion and exclusion criteria in
order to enroll into the trial. For example, social stigma or less awareness of the HIVNET
024 trial might have deterred certain women with low CD4+ counts or high viral loads from
participating in the study. Without knowing the prevalence of risk factors in the general
population, the PAFs calculated based on HIVNET 024 may not be generalizable. Secondly,
the PAF measures a potential reduction of overall LPTs by increasing maternal CD4+ counts
or decreasing maternal viral loads. It does not mean such a reduction would always be
realized. Also, weaning was considered non-informative censoring in the current analysis.
Thus, the assumption was that infants might still be at risk for LPT after weaning, which
might inflate the overall LPT risk. Finally, HIVNET 024 trial did not collect information on
other factors potentially associated with the risk of LPT, e.g., type of breast feeding
(exclusive, predominant, mixed), and there were substantial amounts of missing data for
maternal CD4+ counts and viral loads, although post-hoc sensitivity analysis assuming
several different scenarios shows little impact on the conclusions. These limitations pose
potentially serious challenges to consistent PAF estimates. As a result, PAFs calculated
based on HIVNET 024 need to be further validated.
Nevertheless, our PAF calculations have important implications for the prevention of LPT of
HIV-1. One important implication is that, when an intervention (such as effective use of
ART) is able to increase maternal CD4+ counts or lower maternal viral loads in a high-risk
subgroup, the reduction of overall disease burden of LPT of HIV-1 may be substantial, even
if this high-risk subgroup only accounts for a small proportion of the total population. The
more prevalent the high-risk group, the greater the reduction of LPT incidence that is
expected. For example, in a population with a similar high-risk group as in HIVNET 024,
the PAF could increase quickly from 47.0%, to 64.0%, and to 72.0%, if the prevalence of
the high-risk group in the overall population increased from 25.0%, to 50.0%, and to 75.0%,
respectively. Hence, providing access to and encouraging appropriate use of effective ART
should greatly reduce the LPT incidence when advanced HIV-1 disease is prevalent (as
manifested by lower CD4+ counts and higher plasma viral loads) among pregnant women.
The other important implication is that, if a high-risk subgroup consists of only a small
proportion of individuals in a population, only targeting high-risk subgroups with ART (to
increase maternal CD4+ counts and/or lower maternal viral loads) may not attain a large
reduction of LPTs of HIV-1. For the HIVNET 024 cohort, the PAF was only 16.0%,
implying that there were still a large proportion of LPTs contributed by those women with
less advanced HIV-1 disease. Therefore, additional interventions are necessary to further
lower the risk of LPT among healthier HIV-1-infected women. Such interventions (some of
proven efficacy, and others under study) could include antiretroviral prophylaxis to the
mother and/or the infant during breastfeeding, chemical or heat treatment of breast milk, and
passive or active immunization.
Chen et al. Page 6














We gratefully acknowledge the contribution of the mothers and children who participated in this study. We are also
grateful to the entire study team at each site for their dedication and excellent collaboration. Our thanks are
extended to institutions that contributed to the conduct of this study in each country.
The HIVNET 024 Trial was supported by the HIV Network for Prevention Trials (HIVNET) and sponsored by the
US National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department
of Health and Human Services, through contracts NO1-AI-35173 with Family Health International, NO1-AI-45200
with Fred Hutchinson Cancer Research Center, and subcontract NO1-AI-35173-117/412 with Johns Hopkins
University. In addition, the trial was supported by the HIV Prevention Trials Network (HPTN) and sponsored by
NIAID, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute
on Drug Abuse, the National Institute of Mental Health, and the Office of AIDS Research of the National Institutes
of Health, U.S. Department of Health and Human Services, Harvard University (U01-AI-48006), Johns Hopkins
University (U01-AI-48005), and the University of Alabama at Birmingham (U01-AI-47972). Nevirapine
(Viramune®) for the study was provided by Boehringer Ingelheim Pharmaceuticals, Inc. The conclusions and
opinions expressed in this paper are those of the authors and do not necessarily reflect those of the funding agencies
and participating institutions.
APPENDIX
The HIVNET 024 Team
Protocol Co-Chairs: Taha E. Taha, MD, PhD (Johns Hopkins University Bloomberg School
of Public Health); Robert Goldenberg, MD (University of Alabama at Birmingham);
In-Country Co-Chairs/Investigators of Record: Newton Kumwenda, PhD, George
Kafulafula, MBBS, FCOG (Blantyre, Malawi); Francis Martinson, MD, PhD (Lilongwe,
Malawi); Gernard Msamanga, MD, ScD (Dare es Salaam, Tanzania); Moses Sinkala, MD,
MPH, Jeffrey Stringer, MD (Lusaka, Zambia); US Co-Chairs: Irving Hoffman, PA, MPH
(University of North Carolina, Chapel Hill); Wafaie Fawzi, MD, DrPH (Harvard School of
Public Health );
In-Country Investigators, Consultants and Key Site Personnel: Robin Broadhead, MBBS,
FRCP, George Liomba, MBBS, FRCPath, Johnstone Kumwenda, MBChB, MRCP, Tsedal
Mebrahtu, ScM, Pauline Katunda, MHS, Maysoon Dahab, MHS (Blantyre, Malawi); Peter
Kazembe, MBChB, David Chilongozi CO, MPH, Charles Chasela CO, MPH, George Joaki,
MD, Willard Dzinyemba, Sam Kamanga (Lilongwe, Malawi); Elgius Lyamuya, MD, PhD,
Charles Kilewo, MD, MMed, Karim Manji, MD, MMed, Sylvia Kaaya, MD, MS, Said
Aboud, MD, MMed, Muhsin Sherrif MD, MPH, Elmar Saathoff, PhD, Priya Satow, MPH,
Illuminata Ballonzi, SRN, Gretchen Antelman, ScD, Edgar Basheka, BPharm (Dar es
Salaam, Tanzania); Victor Mudenda, MD, Christine Kaseba, MD, Maureen Njobvu, MD,
Makungu Kabaso, MD, Muzala Kapina, MD, Anthony Yeta, MD, Seraphine Kaminsa, MD,
MPH, Constantine Malama, MD, Dara Potter, MBA, Maclean Ukwimi, RN, Alison Taylor,
BSc, Patrick Chipaila, MSc, Bernice Mwale, BPharm (Lusaka, Zambia);
US Investigators, Consultants and Key Site Personnel: Priya Joshi, BS, Ada Cachafeiro, BS,
Shermalyn Greene, PhD, Marker Turner, BS, Melissa Kerkau, BS, Paul Alabanza, BS, Amy
James, BS, Som Siharath, BS, Tiffany Tribull, MS (UNC-CH); Saidi Kapiga, MD, ScD,
George Seage, PhD (HSPH); Sten Vermund, MD, PhD, William Andrews, PhD, MD,
Deedee Lyon, BS, MT(ASCP) (UAB);
NIAID Medical Officer: Samuel Adeniyi-Jones, MD;
NICHD Medical Officer: Jennifer S. Read, MD, MS, MPH, DTM&H;
Protocol Pharmacologist: Scharla Estep, RPh, MS;
Chen et al. Page 7













Protocol Statisticians: Elizabeth R. Brown, ScD, Tom Fleming, PhD, Anthony Mwatha,
MS, Lei Wang, PhD, Deborah Donnell, PhD, Ying Q. Chen, PhD;
Protocol Virologist: Susan Fiscus, PhD;
Protocol Operations Coordinator: Lynda Emel, PhD;
Data Coordinators: Debra J. Lands, Ed.M, Ceceilia J. Dominique;
Systems Analyst Programmers: Alice H. Fisher, BA, Martha Doyle;
Protocol Specialist: Megan Valentine, PA-C, MS
REFERENCES
1. The Working Group on Mother-to-Child Transmission of HIV. Rates of mother-to-child
transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J Acquir
Immune Defic Syndr Hum Retrovirol. 1995; 8:506–510. [PubMed: 7697448]
2. The Breastfeeding and HIV International Transmission Study (BHITS) Group. Late postnatal
transmission of HIV-1 in breastfed children: an individual patient data metaanalysis. J Infect Dis.
2004; 189:2154–2166. [PubMed: 15181561]
3. The Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS; Geneva, Switzerland:
2008. Report on the Global AIDS Epidemic, Ch. 2. Available at:
http://data.unaids.org/pub/GlobalReport/2008/jc1510_2008_global_report_pp29_62_en.pdf.
4. Mason, E. Positioning paediatric HIV in the child survival agenda: presentation to UNICEF-WHO
consultation. UNICEF; New York: January 11-13. 2006 2006Available at
http://data.unaids.org/pub/GlobalReport/2008/jc1510_2008_global_report_pp325_358_en.pdf.
5. Taha TE, Kumwenda NI, Hoover DR, et al. Association of HIV-1 load and CD4 lymphocyte count
with mortality among untreated African children over one year of age. AIDS. 2000; 14:453–459.
[PubMed: 10770550]
6. Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born
to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2006; 64:1236–1243.
7. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, et al. Mortality in HIV-infected and uninfected
children of HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Synd.r.
2006; 41:504–508.
8. Taha TE, Brown ER, Hoffman IF, et al. A Phase III clinical trial of antibiotics to reduce
chorioamnionitis-related perinatal HIV-1 transmission (HPTN 024). AIDS. 2006; 20:1313–1321.
[PubMed: 16816561]
9. Goldenberg RL, Mwatha A, Read JS, et al. The HPTN 024 Study: The efficacy of antibiotics to
prevent chorioamnionitis and preterm birth. Am J Obs Gyn. 2006; 194:650–661.
10. Chasela C, Chen YQ, Fiscus S, et al. Risk factors for late postnatal transmission of human
immunodeficiency virus type 1 in Sub-Saharan Africa. Pedia Infectious Dis J. 2008; 27:251–256.
11. Levin ML. The occurrence of lung cancer in man. ACTA Unio Internationalis Contra Cancrum.
1953; 9:531–541. [PubMed: 13124110]
12. Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention.
Am J Epidemiol. 1974; 99:325–332. [PubMed: 4825599]
13. Chen YQ, Hu CC, Wang Y. Attributable risk function in the proportional hazards model for
censored time-to-event. Biostatist. 2006; 7:515–529.
14. Rockhill B, Newman B, Weinberg B. Use and misuse of population attributable fractions. Amer J
Pub Health. 88:15–19. [PubMed: 9584027]
15. Allison P. Discrete-time methods for the analysis of event histories. Social Method. 1982; 13:61–
98.
Chen et al. Page 8













16. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared
with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda:
HIVNET 012 randomised trial. Lancet. 1999; 354:795–805. [PubMed: 10485720]
17. Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk,
mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis.
1999; 180:93–98. [PubMed: 10353866]
18. Embree JE, Njenga S, Datta P, et al. Risk factors for postnatal mother-child transmission of HIV-1.
AIDS. 2000; 14:2535–2541. [PubMed: 11101065]
19. Leroy V, Karon JM, Alioum A, et al. Postnatal transmission of HIV-1 after a maternal short-course
zidovudine peripartum regimen in West Africa. AIDS. 2003; 17:1493–1501. [PubMed: 12824787]
20. Pillay K, Coutsoudis A, York D, et al. Cell-free virus in breast milk of HIV-1-seropositive women.
J Acquir Immune Defic Syndr. 2000; 24:330–336. [PubMed: 11015149]
21. Contopoulos-Ioannidis DG, Ioannidis JPA. Maternal cell-free viremia in the natural history of
perinatal HIV-1 transmission: a meta-analysis. J Acquir Immune Defic Syndr Hum Retrovirol.
1998; 18:126–133. [PubMed: 9637577]
22. Richardson BA, John-Stewart GC, Hughes JP, et al. Breast-milk infectivity in human
immunodeficiency virus type 1-infected mothers. J Infect Dis. 2003; 187:736–740. [PubMed:
12599046]
23. Taha TE, Hoover DR, Kumwenda NI, et al. Late postnatal transmission of HIV-1 and associated
factors. J Infect Dis. 2007; 196:10–14. [PubMed: 17538877]
24. Mock PA, Shaffer N, Bhadrakom C, et al. Maternal viral load and timing of mother-to-child HIV
transmission, Bangkok, Thailand. AIDS. 1999; 13:407–414. [PubMed: 10199232]
25. Lin DY, Fleming TR, DeGruttola V. Estimating the proportion of treatment effect explained by a
surrogate marker. Statist Med. 1997; 16:1515–1527.
Chen et al. Page 9














Scatter plot of maternal viral loads (log10 copies/ml) versus maternal CD4+ counts (cells/
mm^3)
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Kaplan–Meier Estimates for Proportion of HIV–1 Uninfected Infants During the Late
Postnatal Period
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TABLE 2
Incidences of Late Postnatal Transmission of HIV-1
Late Postnatal Period* Infant-Years Incidences Incidence Rate† 95% CI†
42-182 Days 437.8 53 11.9% 8.9%, 15.6%
183-365 Days 394.8 31 7.9% 5.3%, 11.1%
CI, Confidence Interval
*
Number of days after birth
†
Based on person-year analysis
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